Timely recovery after subclinical heart failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503135-33-00

Enrollment

130

Registered

2023-07-28

Start date

2024-03-26

Completion date

Unknown

Last updated

2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical heart failure

Brief summary

Left ventricular hypertrophy (Left ventricular mass index ≥95 g/m2), Concentric remodeling (relative wall thickness >0.43), Impaired systolic function (ejection fraction <55%), Significant valve dysfunction (American Society of Echocardiography guidelines), Signs of myocardial infarction (MI)

Detailed description

Blood pressure, Plasma volume, Quality of life, behavior and symptoms, Metabolic syndrome, Renin-angiotensin-aldosterone system, Novel biomarkers

Interventions

DRUGValsartan 40 mg capsules

DRUGhard

DRUGPerindopril 2 mg

DRUGTablets

DRUGNitrospray 0

DRUG4 mg/devā aerosols lietošanai zem mēles

DRUGšķīdums

DRUGALBUMIN

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Left ventricular hypertrophy (Left ventricular mass index ≥95 g/m2), Concentric remodeling (relative wall thickness >0.43), Impaired systolic function (ejection fraction <55%), Significant valve dysfunction (American Society of Echocardiography guidelines), Signs of myocardial infarction (MI)	—

Secondary

Measure	Time frame
Blood pressure, Plasma volume, Quality of life, behavior and symptoms, Metabolic syndrome, Renin-angiotensin-aldosterone system, Novel biomarkers	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026